Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-arm, Open-label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma

NCT02329717 is registered in ClinicalTrials.gov with Phoenix Biotechnology, Inc as lead sponsor.

NCT NCT02329717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02329717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-arm, Open-label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma
Lead sponsor
Phoenix Biotechnology, Inc
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2015
Completion date
December 31, 2016
Enrollment
50 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer